Hill-Rom Holdings (NYSE: HRC) and Meridian Bioscience (NASDAQ:VIVO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitabiliy, analyst recommendations, institutional ownership and valuation.
This is a breakdown of current ratings and recommmendations for Hill-Rom Holdings and Meridian Bioscience, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Hill-Rom Holdings presently has a consensus target price of $87.80, indicating a potential upside of 16.57%. Meridian Bioscience has a consensus target price of $14.33, indicating a potential upside of 4.62%. Given Hill-Rom Holdings’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Hill-Rom Holdings is more favorable than Meridian Bioscience.
Risk & Volatility
Hill-Rom Holdings has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, Meridian Bioscience has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.
Insider and Institutional Ownership
83.9% of Hill-Rom Holdings shares are held by institutional investors. Comparatively, 85.9% of Meridian Bioscience shares are held by institutional investors. 2.2% of Hill-Rom Holdings shares are held by company insiders. Comparatively, 2.3% of Meridian Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Hill-Rom Holdings pays an annual dividend of $0.72 per share and has a dividend yield of 1.0%. Meridian Bioscience pays an annual dividend of $0.50 per share and has a dividend yield of 3.6%. Hill-Rom Holdings pays out 41.6% of its earnings in the form of a dividend. Meridian Bioscience pays out 98.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Meridian Bioscience has raised its dividend for 6 consecutive years. Meridian Bioscience is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
This table compares Hill-Rom Holdings and Meridian Bioscience’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Hill-Rom Holdings and Meridian Bioscience’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Hill-Rom Holdings||$2.71 billion||1.83||$465.30 million||$1.73||43.54|
|Meridian Bioscience||$197.57 million||2.93||$52.73 million||$0.51||26.86|
Hill-Rom Holdings has higher revenue and earnings than Meridian Bioscience. Meridian Bioscience is trading at a lower price-to-earnings ratio than Hill-Rom Holdings, indicating that it is currently the more affordable of the two stocks.
Hill-Rom Holdings beats Meridian Bioscience on 10 of the 17 factors compared between the two stocks.
About Hill-Rom Holdings
Hill-Rom Holdings, Inc. is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions. The Company sells and rents its specialty frames and surfaces, and mobility solutions, as well as its clinical workflow solutions, in the United States and Canada through its North America Patient Support Systems segment, and in regions outside of the United States and Canada through its International Patient Support Systems segment. Its Front Line Care segment globally sells and rents respiratory care products, and sells medical diagnostic equipment and a diversified portfolio of devices that assess, diagnose, treat and manage a range of illnesses and diseases. Under its Surgical Solutions segment, the Company sells its surgical products globally.
About Meridian Bioscience
Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.
Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with our FREE daily email newsletter.